Cite
HARVARD Citation
Papp, K. et al. (2017). Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis. British journal of dermatology. pp. 1562-1574. [Online].